Ascendis Pharma A/S
ASNDDrugs in Pipeline
10
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Aug 6, 2026
4wMarket Overview
Stock performance and key metrics
2 upcoming, 1 past
How ASND's past catalysts played out
Once weekly subcutaneous injection of TransCon hGH
Growth Hormone Deficiency, Pediatric
TransCon CNP
Achondroplasia
Lonapegsomatropin
Growth Hormone Deficiency
TransCon hGH
Growth Hormone Deficiency, Pediatric
TransCon IL-2 β/γ
Advanced Solid Tumor
ACP-001 (TransCon hGH)
Adult Growth Hormone Deficiency
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Achondroplasia
ACP-001
Growth Hormone Deficiency (GHD)
Navepegritide
Achondroplasia
Somatropin
Turner Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Once weekly subcutaneous injection of TransCon hGH | Phase 3 | Growth Hormone Deficiency, Pediatric | - | - |
TransCon CNP | Phase 3 | Achondroplasia | - | - |
Lonapegsomatropin | Phase 3 | Growth Hormone Deficiency | - | - |
TransCon hGH | Phase 3 | Growth Hormone Deficiency, Pediatric | - | - |
TransCon IL-2 β/γ | Phase 2 | Advanced Solid Tumor | - | - |
ACP-001 (TransCon hGH) | Phase 2 | Adult Growth Hormone Deficiency | - | - |
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections | Phase 2 | Achondroplasia | - | - |
ACP-001 | Phase 2 | Growth Hormone Deficiency (GHD) | - | - |
Navepegritide | Phase 2 | Achondroplasia | - | - |
Somatropin | Phase 2 | Turner Syndrome | - | - |
Achondroplasia
3 drugs in this indication
Growth Hormone Deficiency (GHD)
1 drug in this indication
Adult Growth Hormone Deficiency
1 drug in this indication
Growth Hormone Deficiency, Pediatric
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Ascendis Pharma A/S's drug pipeline?→
CatalystAlert tracks 10 drug candidates in Ascendis Pharma A/S's (ASND) pipeline across Phase 3, Phase 2. Its lead program is Once weekly subcutaneous injection of TransCon hGH (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ascendis Pharma A/S's next FDA catalyst?→
Ascendis Pharma A/S's (ASND) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ASND biotech catalysts?→
Add ASND to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ascendis Pharma A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.